Advances in the management of Crohn's disease: Economic and clinical potential of infliximab

Clinical Therapeutics

Volumn 20, Issue 5, 1998, Pages 1009-1028

  Hanauer, Stephen B ^a   Cohen, Russell D ^a   Becker III, Russell V ^b   Larson, Leanne R ^b   Vreeland, Mary Glenn ^b  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b ClinTrials Ovation   (United States)

Author keywords

Costs; Crohn's disease; Economics; Infliximab

Indexed keywords

AMINOSALICYLIC ACID DERIVATIVE; ANTIBIOTIC AGENT; ANTIDIARRHEAL AGENT; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MESALAZINE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL FEATURE; COST OF ILLNESS; CROHN DISEASE; DISEASE COURSE; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HUMAN; PATHOPHYSIOLOGY; QUALITY OF LIFE; SURGICAL APPROACH;

EID: 0031759492     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(98)80082-9     Document Type: Article

References (66)

1. Eisen GM, Sandler RS. Update on the epidemiology of IBD. Prog Inflamm Bowel Dis. 1994;15:1-8.
2. Hanauer S, Meyers S. Management of Crohn's disease in adults. Am J Gastroenterol. 1997;92:559-566.
3. Russel MG, Stockbrugger RW. Epidemiology of inflammatory bowel disease. Scand J Gastroenterol. 1996;31:417-427.
4. Tooson JD, Varilek GW. Inflammatory diseases of the colon. Inflamm Dis. 1998; 98:46-74.
5. Calkins B, Mendeloff A. Epidemiology of inflammatory bowel disease. Epidemiol Rev. 1996;8:60-91.
6. Hay JW, Hay AR. Inflammatory bowel disease: Costs-of-illness. J Clin Gastroenterol. 1992;14:309-317.
7. Medications for Inflammatory Bowel Disease. New York: Crohn's and Colitis Foundation of America, Inc.; 1995.
8. Hanauer SB, Schulman MI. Inflammatory bowel disease: New therapeutic approaches. Gastroenterol Clin North Am. 1998;24:523-540.
9. Selby W. Clinical perspectives in inflammatory bowel disease. Aust New Zealand J Med. 1996;26:15-19.
10. Loftus EV Jr, Silverstein MD, Sandborn WJ, et al. Crohn's disease in Olmsted County, Minnesota, 1940-1993: Incidence, prevalence, and survival. Gastroenterology. 1998;114:1161-1168.
11. Sartor RB. Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn's disease. Gastroenterol Clin North Am. 1995;24:475-507.
12. Ottaway CA. Role of the neuroendocrine system in cytokine pathways in inflammatory bowel disease. Aliment Pharmacol Ther. 1996;10(Suppl):10-15.
13. Sartor RB. Cytokines in intestinal inflammation: Pathophysiological and clinical considerations. Gastroenterology. 1994; 106:533-539.
14. Williams D, Coller J, Corman M, et al. Anal complication in Crohn's disease. Dis Colon Rectum. 1981;24:22-24.
15. Hanauer SB. Inflammatory bowel disease. NEJM. 1996;334:841-847.
16. Gregor JC, McDonald JWD, Klar N, et al. An evaluation of utility measurement in Crohn's disease. Inflamm Bowel Dis. 1997;3:265-276.
17. Best WR, Becket JM, Singleton JW. Re-derived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI). Gastroenterology. 1979;77:843-846.
18. Irvine EJ. Quality of life in inflammatory bowel disease and other chronic diseases. Scand J Gastroenterol. 1996;221:26-28.
19. de Boer AG, Wijker W, Bartelsman JF, de Haes HC. Inflammatory bowel disease questionnaire: Cross-cultural adaption and further validation. Eur J Gastroenterol Hepatol. 1995;7:1043-1050.
20. Physician's GenRx. St. Louis, Mo: C.W. Mosby; 1998:II-1800.
21. Elton E, Hanauer SB. Review article: The medical management of Crohn's disease. Aliment Pharmacol Ther. 1996;10:1-22.
22. Singleton JW, Hanauer SB, Gitnick GL, et al. Mesalamine capsules for the treatment of active Crohn's disease: Results of a 16-week trial. Gastroenterology. 1993; 104:1293-1301.
23. Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn's Disease Study (ECCDS): Results of drug treatment. Gastroenterology. 1984;84:249-266.
24. Caprilli R, Andreoli A, Capurso L, et al. Oral mesalazine (5-aminosalicylic acid: Asacol) for the prevention of post-operative recurrence of Crohn's disease. Aliment Pharmacol Ther. 1994;8:35-43.
25. McLeod RS, Wolff BG, Steinhart AH, et al. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology. 1995; 109:404-413.
26. Schroder H, Price-Evans DA. Acetylator phenotype and adverse events of sulphasalazine in healthy subjects. Gut. 1972; 13:278-284.
27. Nielson OH. Sulfasalazine intolerance: A retrospective survey of the reasons for discontinuing treatment with sulfasalazine in patients with chronic inflammatory bowel disease. Scand J Gastroenterol. 1982; 17:389-393.
28. Taffet SL, Das KM. Sulfasalazine: Adverse effects and desensitization. Drug Saf. 1983;28:833-842.
29. Singleton JW, Law DH, Kelley ML, et al. National Cooperative Crohn's Disease Study: Adverse reactions to study drugs. Gastroenterology. 1979;77:870-882.
30. Hanauer SB, Meyers S, Sachar DB. The pharmacology of antiinflammatory drugs in inflammatory bowel disease. In: Kirsner JB, ed. Inflammatory Bowel Disease. 4th ed. Baltimore, Md: Williams & Wilkins; 1995:643-663.
31. Hanauer SB, Stathopoulos G. Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease. Drug Saf. 1991;6:192-219.
32. Summers RW, Switz DM, Sessions JT Jr, et al. National Cooperative Crohn's Disease Study: Results of drug treatment. Gastroenterology. 1979;77:847-869.
33. Bitton A, Peppercorn MA. Inflammatory bowel disease: Medical management of specific clinical presentations. Gastroenterol Clin North Am. 1995;24:541-558.
34. Thiesen A, Thomson AB. Review article: Older systemic and newer topical glucocorticosteroids and the gastrointestinal tract. Aliment Pharmacol Ther. 1996; 10: 487-496.
35. Hamedani R, Feldman RD, Feagan BG. Review article. Drug development in inflammatory bowel disease: Budesonide - A model of targeted therapy. Aliment Pharmacol Ther. 1997;11:98-108.
36. Rutgeerts P, Lofberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn's disease. NEJM. 1994;331:842-845.
37. Thomsen OO, Cortot A, Jewell D, et al. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. NEJM. 1998;339:370-374.
38. Lofberg R, Rutgeerts P, Malchow H, et al. Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study. Gut. 1996;39:82-86.
39. Bickston SJ, Cominelli F. Treatment of Crohn's disease at the turn of the century. NEJM. 1998;339:401-402. Editorial.
40. Present D, Korelita BI, Wisch N, et al. Treatment of Crohn's disease with 6-mercaptopurine. NEJM. 1998;302:981-987.
41. Present D, Meltzer S, Krumholz M, Wolke A. 6-Mercaptopurine in the management of inflammatory bowel disease: Short- and long-term toxicity. Ann Intern Med. 1989; 111:641-649.
42. Present D, Mayer L, VanDeventer SJH, et al. Anti-TNF-alpha chimeric antibody (cA2) is effective in the treatment of the fistulae of Crohn's disease: A multi-center, randomized, double-blind, placebo-controlled study. Proceedings of the 62nd Annual Scientific Meeting of the American College of Gastroenterology 1997. November 3-5, 1997: Chicago, Illinois. Abstract.
43. Sandborn W, Tremaine W. Measurement of thiopurine methyltransferase (TMPT) activity in patients with inflammatory bowel disease (IBD) does not predict side effects from treatment with 6-mercaptopurine (6-MP) or azathioprine. Gastroenterology. 1993;104:A774. Abstract.
44. O'Brien JJ, Bayless TM, Bayless JA. Use of azathioprine or 6-mercaptopurine in the treatment of Crohn's disease. Gastroenterology. 1991; 101:39-46.
45. Bernstein LH, Frank MS, Brandt LJ, Boley SJ. Healing of perineal Crohn's disease with metronidazole. Gastroenterology. 1980;79:357-365.
46. Brandt LJ, Bernstein LH, Boley SJ, Frank MS. Metronidazole therapy for perineal Crohn's disease: A follow-up study. Gastroenterology. 1982;83:383-387.
47. Seidman EG, Boutiller L, Weber AM, et al. Elemental diet versus prednisone as primary treatment of Crohn's disease. Gastroenterology. 1986;90:A1625. Abstract.
48. Gorard DA, Hunt JB, Payne-James JJ, et al. Initial response and subsequent cures of Crohn's disease treated with elemental diet or prednisolone. Gut. 1993;34:1198-1202.
49. Gonzalez-Huix F, de Leon R, Fernandez-Banares F, et al. Polymeric enteral diets as primary treatment of active Crohn's disease: A prospective steroid controlled trial. Gut. 1993;34:778-782.
50. Glotzer DJ. Surgical therapy for Crohn's disease. Gastroenterol Clin North Am. 1995;24:577-597.
51. Van Deventer SJ, Camoglio L. Monoclonal antibody therapy of inflammatory bowel disease. Pharm World Sci. 1992; 19:55-59.
52. Sands BE. Biologic therapy for inflammatory bowel disease. Inflamm Bowel Dis. 1993;3:95-113.
53. Introduction to TNF-cA2/C01168t22. Malvern, Pa: Centocor, Inc; 1996.
54. Van Deventer S. Tumour necrosis factor and Crohn's disease. Gut. 1997;40:443-448.
55. Scallon BJ, Moore MA, Trinh H, et al. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector function. Cytokine. 1995;April 7:251-259.
56. Single infusion of chimeric monoclonal anti-TNF antibody (cA2) in Crohn's disease - Study C0168T08. Malvern, Pa: Centocor, Inc; 1996.
57. Van Dullemen HM, Van Deventer SJH, Hommes DW, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology. 1995;109:129-135.
58. Targan SR, Hanauer SB, Sander HH, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. NEJM. 1997;337:1029-1035.
59. Rutgeerts P, Haens GD, van Deventer S, et al. Retreatment with anti-TNF-alpha chimeric antibody (cA2) effectively maintains cA2-induced remission in Crohn's disease. Gastroenterology. 1997;112: A1078. Abstract.
60. Hay AR, Hay JW. Inflammatory bowel disease: Medical cost algorithms. J Clin Gastroenterol. 1992;14:318-327.
61. Bureau of Labor Statistics. Medical Care Services Component of the Consumer Price Index. Washington, DC: US Department of Labor; 1997.
62. Mehl B, Santell JP. Projecting future drug expenditures - 1998. Am J Health-Syst Pharm. 1998;55:127-136.
63. Cohen RD, Larson LR, Roth JM. Crohn's disease hospitalizations: Where does the money go? Am J Gastroenterol. 1998; 93:1754. Abstract.
64. National Disease and Therapeutic Index, Fourth Quarter 1997 (January 1997 to December 1997). Plymouth Meeting, Pa: IMS America, Ltd; 1997.
65. National Institute of Diabetes and Digestive and Kidney Diseases: Digestive Diseases in the United States: Epidemiology and Impact. Washington, DC: US Department of Health and Human Services, Public Health Service; 1994:511-550.
66. Hendriksen C, Kreiner SB, Binder V. Long term prognosis in ulcerative colitis - based on results from a regional patient group from the county of Copenhagen. Gut. 1985;26:158-163.